Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer

医学 蛋白尿 伦瓦提尼 肾细胞癌 内科学 舒尼替尼 肿瘤科 癌症 肾功能 索拉非尼 肾癌 入射(几何) 甲状腺癌 肝细胞癌 胃肠病学 肾 光学 物理
作者
Taigo Kato,Ryuichi Mizuno,Hideaki Miyake
出处
期刊:International Journal of Urology [Wiley]
标识
DOI:10.1111/iju.15409
摘要

Abstract Vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitors (VEGFR‐TKIs) are often used for treatment of several types of cancer; however, they are associated with an increased risk of proteinuria, sometimes leading to treatment discontinuation. We searched PubMed and Scopus to identify clinical studies examining the incidence and risk factors for proteinuria caused by VEGFR‐TKIs in patients with renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. The global incidence of proteinuria ranged from 6% to 34% for all grades of proteinuria, and from 1% to 10% for grade ≥3 proteinuria. The incidence of proteinuria did not differ significantly by cancer type, but in all three cancer types, there was a trend toward a higher incidence of proteinuria with lenvatinib than with other VEGFR‐TKIs. In terms of risk factors, the incidence of proteinuria was significantly higher among Asians (including Japanese) compared with non‐Asian populations. Other risk factors included diabetes mellitus, hypertension, and previous nephrectomy. When grade 3/4 proteinuria occurs, patients should be treated according to the criteria for dose reduction or withdrawal specified for each drug. For grade 2 proteinuria, treatment should be continued when the benefits outweigh the risks. Referral to a nephrologist should be considered for symptoms related to decreased renal function or when proteinuria has not improved after medication withdrawal. These management practices should be implemented universally, regardless of the cancer type.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Xide完成签到,获得积分10
1秒前
冷傲的小甜瓜完成签到,获得积分20
1秒前
1秒前
高登登发布了新的文献求助10
2秒前
桐桐的应助被2024020847采纳,获得10
2秒前
2秒前
3秒前
杨一完成签到,获得积分10
3秒前
科研通AI6.4的应助被大吱吱采纳,获得10
3秒前
大气的莆完成签到,获得积分10
4秒前
4秒前
5秒前
cheng完成签到,获得积分10
5秒前
5秒前
qz关闭了qz的文献求助
5秒前
5秒前
NN发布了新的文献求助30
6秒前
Irene发布了新的文献求助10
6秒前
6秒前
6秒前
陈陈陈完成签到 ,获得积分10
7秒前
llllll完成签到,获得积分20
7秒前
8秒前
浮生绘完成签到,获得积分10
8秒前
cheng发布了新的文献求助10
8秒前
所所的应助被Atue采纳,获得10
9秒前
9秒前
9秒前
elvira的应助被舒适的秋尽采纳,获得10
9秒前
CodeCraft的应助被kuaikuai采纳,获得10
9秒前
10秒前
丘比特的应助被Irene采纳,获得10
10秒前
JamesPei的应助被shidewu采纳,获得10
10秒前
11秒前
11秒前
搜集达人的应助被张张采纳,获得10
11秒前
不安易文发布了新的文献求助10
12秒前
jiajiajai完成签到,获得积分10
12秒前
Youzi完成签到,获得积分10
12秒前
无花果的应助被玩家666采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178484
求助须知:如何正确求助?哪些是违规求助? 9569318
关于积分的说明 21803439
捐赠科研通 7773381
什么是DOI,文献DOI怎么找? 3432819
关于科研通互助平台的介绍 2556838
邀请新用户注册赠送积分活动 2478441